Skip to main content
. 2023 Mar 28;14:1733. doi: 10.1038/s41467-023-37254-w

Fig. 2. Design strategy for covalent PLpro inhibition.

Fig. 2

a X-ray co-crystal structure of ubiquitin-propargylamine (cyan) covalently bound to Cys111 in PLpro (tan) from PDB entry 6XAA12. Selected residues from PLpro and the LRGG motif of ubiquitin (cyan) are labeled and shown in stick representation. b Crystal structure of GRL0617 (cyan) bound to PLpro (PDB entry 7CMD)18. The distance between Sγ of Cys111 and the tolyl methyl of GRL0617 is labeled. c Components of covalent PLpro inhibitor candidates consisting of various electrophiles, a Gly-Gly mimetic linker, and the GRL0617 core. Reactive carbons on electrophiles are labeled with asterisks. d Mechanism of covalent bond formation between Cys111 and an inhibitor candidate with a fumarate ester electrophile.